Arcus Biosciences, Inc.
No enriched coverage for $RCUS in the last 7 days.
No SEC Form 4 filings for $RCUS in the last 30 days.
See all $RCUS insider activity →Wedbush analyst Robert Driscoll maintained an Outperform rating and $43 price target for Arcus Biosciences (RCUS). The company is developing cancer treatments, with its lead drug Casdatifan in trials for renal cell carcinoma. Arcus plans to present new data on October 20, 2026.
Arcus Biosciences (RCUS) shares rose 3.4% after TD Cowen initiated coverage with a Buy rating. Analyst Tara Bancroft cited potential for casdatifan to lead in renal cell carcinoma treatment, noting its progression-free survival advantage over Welireg. Bancroft highlighted data that could derisk Phase III trials and position casdatifan in the $10B+ market.
Arcus Biosciences (NYSE:RCUS) and Summit Therapeutics (NASDAQ:SMMT) announced a clinical trial collaboration combining Arcus’s casdatifan (HIF-2α inhibitor) with Summit’s ivonescimab (PD-1/VEGF bispecific) for clear cell renal cell carcinoma, including first-line metastatic disease. Summit supplies ivonescimab; Arcus runs the ARC-20 cohort. Initial data expected mid-2027. RCUS reported Q2 2026 revenue of $41M and net loss of $91M, with $775M cash.
Recent RCUS coverage spans financial news, insider activity and market movers.
Analyst upgrade with a higher price target may lift the stock.
Analyst upgrade likely supports short‑term upside as investors add to position.
New combination trial and ARC-20 cohort plan can shift expectations for casdatifan’s clinical trajectory and funding needs into 2027 readouts.
The filing adds time-specific catalysts (milestone cash, multiple ARC-20 readouts, and PEAK-1 enrollment acceleration) that can re-rate casdatifan probability-weighted value.
The PT hike is driven by expanded modeled revenue assumptions for casdatifan in broad 1L ccRCC, plus a plan to generate Phase 3-enabling data via ARC-20 enrollment.
AlphAI scores every news story that mentions RCUS with an AI model for sentiment and relevance, and aggregates insider trades from Arcus Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wedbush analyst Robert Driscoll maintained an Outperform rating and $43 price target for Arcus Biosciences (RCUS). The company is developing cancer treatments, with its lead drug Casdatifan in trials for renal cell carcinoma. Arcus plans to present new data on October 20, 2026.
1 min readArcus Biosciences (RCUS) shares rose 3.4% after TD Cowen initiated coverage with a Buy rating. Analyst Tara Bancroft cited potential for casdatifan to lead in renal cell carcinoma treatment, noting its progression-free survival advantage over Welireg. Bancroft highlighted data that could derisk Phase III trials and position casdatifan in the $10B+ market.
1 min readArcus Biosciences (NYSE:RCUS) and Summit Therapeutics (NASDAQ:SMMT) announced a clinical trial collaboration combining Arcus’s casdatifan (HIF-2α inhibitor) with Summit’s ivonescimab (PD-1/VEGF bispecific) for clear cell renal cell carcinoma, including first-line metastatic disease. Summit supplies ivonescimab; Arcus runs the ARC-20 cohort. Initial data expected mid-2027. RCUS reported Q2 2026 revenue of $41M and net loss of $91M, with $775M cash.
6 min readArcus Biosciences, Inc. (RCUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update August 5, 2026 • Arcus executes on strategy to establish casdatifan as a backbone therapy across each line of treatment for clear cell renal cell carcinoma (ccRCC), includi
7 min readHC Wainwright raised its Arcus Biosciences (RCUS) price forecast 33%, from $32 to $45, citing Arcus’ push to position casdatifan in first-line clear cell renal cell carcinoma. Arcus said it is enrolling a Phase 1/1b ARC-20 cohort to support a Phase 3 start by year-end 2026. The model assumes about $2.2B peak unadjusted 1L revenues.
4 min readJaen Juan C. (President) sold 68,569 indirectly-held shares of Arcus Biosciences, Inc. (RCUS) at an average of $29.63 ($28.61–$30.05, $2.03M total) across 3 trades over 2026-07-09 to 2026-07-10 under a Rule 10b5-1 trading plan.
2 min readJaen Juan C. (President) sold 31,431 indirectly-held shares of Arcus Biosciences, Inc. (RCUS) at an average of $27.92 ($27.03–$29.66, $0.88M total) across 4 trades over 2026-06-22 to 2026-06-24 under a Rule 10b5-1 trading plan.
2 min readArcus Biosciences, Inc. (RCUS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. rcus-20260611 false 0001724521 0001724521 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 8-K ________________________________________________________ CURRENT REPORT Pursua
2 min readAzoy Alexander (Chief Accounting Officer) sold 2,562 shares of Arcus Biosciences, Inc. (RCUS) at $25.77 on 2026-06-01 under a Rule 10b5-1 trading plan.
1 min readArcus Biosciences (RCUS) stock rose 7.8% on impressive volume due to investor confidence in its pipeline candidates for cancer. Despite this, the company is expected to post a quarterly loss, and the consensus EPS estimate has remained unchanged, suggesting that sustained strength might depend on future earnings estimate revisions. Investors are advised to monitor RCUS and consider its Zacks Rank #3 (Hold) status.
4 min read
